Ponoi Management, LLC
Follow13F filer, CIK 1720702, San Francisco, CA
Ponoi Management, LLC reported $108,463,000 across 4 holdings for the quarter ended 2021-12-31, in a 13F-HR filed 2022-02-11.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-22-002169
- Period
- 2021-12-31
- Reported value
- $108M
- Holdings
- 4
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| NRIXreduced | -234,451 | -$6.79M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q4 2021
Share positions as resolved from 13F-HR 0000950123-22-002169, largest first. % of portfolio is the value over $108,463,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 1,599,417 | $58.7M | 54.16% | 0 | |||
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 1,298,908 | $23M | 21.21% | 0 | |||
| RVMDREVOLUTION MEDICINES INC | 685,011 | $17.2M | 15.9% | 0 | Timeline | ||
| NRIXNURIX THERAPEUTICS INC | 327,122 | $9.47M | 8.73% | -234,451 | Timeline |
How Q4 2021 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-22-002169 | base | 2022-02-11 | acceptance time not in the bulk data set |